Clinical Trials Logo

Clinical Trial Summary

This trial develops and studies how well a patient decision aid works in supporting decision-making about when to start or stop new drugs, join clinical trials, or continue active cancer monitoring for patients with medullary thyroid cancer and their caregivers. Developing a patient decision aid may help patients with medullary thyroid cancer make well-informed decisions about their cancer care and be able to discuss their preferences with their doctors.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess patient/survivor, caregiver/family member, and provider decision-making needs. II. To design and develop an initial patient decision aid prototype. III. To pilot test its acceptability. IV. To evaluate the acceptability and usability of the decision aid prototype from patients/survivors, caregivers and providers in a real world environment. OUTLINE: Participants use decision aid and complete questionnaire. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03892993
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Elizabeth G Grubbs, MD
Phone (713) 792-0665
Email eggrubbs@mdanderson.org
Status Recruiting
Phase N/A
Start date April 9, 2019
Completion date August 1, 2028

See also
  Status Clinical Trial Phase
Completed NCT01204476 - Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Phase 1
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT02592356 - Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer N/A
Completed NCT01709435 - Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Phase 1
Active, not recruiting NCT02293954 - Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer N/A
Active, not recruiting NCT02867592 - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase 2
Completed NCT01155258 - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1
Completed NCT00519896 - Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Phase 2
Recruiting NCT04759911 - Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Phase 2
Completed NCT00134043 - Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Phase 2
Completed NCT00118248 - Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Phase 2
Completed NCT00655655 - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00068497 - Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer N/A
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1